Myovant eyes third NDA for relugolix after endometriosis readout

An NDA submission for an endometriosis therapy could come early next year from Myovant, whose shares gained $2.49 (14%) to $19.90 Tuesday after the company posted positive data for relugolix in a second Phase III trial for the disease.

In the SPIRIT 1 study, a combination of relugolix plus estradiol and norethindrone acetate met the co-primary endpoints and all seven key secondary endpoints in women with pain associated with endometriosis...